Prasugrel and Glycoprotein IIb/IIIa Inhibition in Percutaneous Coronary Intervention
In an observational analysis of TRITON-TIMI 38 data, prasugrel outperformed clopidogrel in patients with ACS, whether or not they received GP IIb/IIIa inhibitors.
Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Sign In
Sign Up
Print subscribers
Activate your free online account for full access to all site content and features.
Other visitors
Subscribe for full access to all site content and features. ($99/year)
Purchase a site pass for full access to all articles. ($19/7 days)
Or, simply register for free access to email alerts, site features, and article archives. (FREE)